Windlas Biotech Ltd
WINDLASWindlas Biotech Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it.
Biggest watch item: the P/E sits at the 71st percentile of its own range — the multiple has already done part of the work.
The price is building a base (7 weeks in) while the P/E sits at the 71st percentile of its own 5-year range. Underneath, the last four quarters read mixed — profit +0.0% year on year, and 152% of the last 3 years' profit arrived as cash. What settles it: the next one or two quarters of delivery.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Windlas Biotech Ltd trades at ₹844, building a base and 7 weeks into that stage. That is +1.2% against its own 200-day average. It sits at 37% of a 52-week range of ₹723 to ₹1,048. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks.
Today the stock is building a base — week 7 of stage 1, confirmed. At ₹844 it trades +1.2% versus its 200-day average and sits at 37% of its 52-week range (₹723–₹1,048).
Against the market, two honest reads. Cumulative: over the last 4.9 years the stock moved +130% while the NIFTY 500 moved +66% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 4 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 71st percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Windlas Biotech Ltd trades at 26.6× P/E, at the pricey end of its own range (71st percentile). Its long-run median P/E is 21.2×, measured across 4.9 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 26.6× is at the pricey end of its own range (71st percentile), against a long-run median of 21.2× measured over 4.9 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +8.2% against a −8.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 5y, of the +18.1%/yr price move, ~−8.4%/yr came from earnings growth and ~+26.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
A quarterly PEG curve, which only the second data source carries, is not drawn on this page: its two data sources do not share enough overlapping reported history to be compared. A figure nobody could check is not used to price growth — the gap is a decision, not missing data.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Windlas Biotech Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE holding at 16.0% — the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +18.9% | +20.8% | +16.1% | — |
| Profit | +8.2% | +15.4% | +32.8% | — |
| EPS | +8.2% | +16.3% | +5.0% | — |
| Share price | −8.6% | +37.1% | +18.1% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
52.8/100 — rank 11 of 24 in Pharma - API & CRAMS · 77% evidence confidence
Windlas Biotech Ltd scores 52.8 out of 100 against the 24 companies it is compared with in Pharma - API & CRAMS, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 17.5 + 14.8 + 11.7 + 8.8 = 52.8. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Windlas Biotech Ltd reported ₹238 Cr of revenue in the Mar 26 quarter, +17.2% year on year. That is the 10th straight quarter of year-on-year growth. Over 8 years it has compounded at 12.5% a year. The last full year, FY26, came in at ₹904 Cr. The last four reported quarters add to ₹903 Cr.
Windlas Biotech Ltd reported ₹238 Cr of revenue in the Mar 26 quarter, +17.2% year on year. That is the 10th straight quarter of year-on-year growth. Over 8 years it has compounded at 12.5% a year. The last full year, FY26, came in at ₹904 Cr. The last four reported quarters add to ₹903 Cr.
FY26 revenue came in at ₹904 Cr (+18.9% on the year), capping 8 years at 12.5% compound. The latest quarter (Mar 26) printed ₹238 Cr, +17.2% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +18.9% growth against the decade's 12.5% — the current year is running faster than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +18.8% over the last 4 quarters against +19.6%/yr over the last 8 — stabilising; TTM profit +9.8% vs +7.5%/yr — stabilising.
→ Revenue grew — did margins hold as it scaled? Next: 11.0% this quarter (−2.0 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Windlas Biotech Ltd's operating margin is 11.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 10.0% to 13.0%. The current quarter sits inside that band.
Windlas Biotech Ltd's operating margin is 11.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 10.0% to 13.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 11.0%, −2.0 pp against the same quarter a year ago. Across 9 fiscal years the operating margin has ranged 10.0%–13.0%.
🚨 Why the margin moved: operating margin went −2.0 pp year on year while gross margin went +0.1 pp — the loss came mostly below the gross line: operating leverage, with costs spread over a bigger revenue base.
→ Margins slipped — did that reach the bottom line? Next: profit +0.0% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Windlas Biotech Ltd earned ₹16.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹66.0 Cr. The 8-year compound rate is 25.1%. That is 6.7% of the quarter's revenue. The same quarter a year earlier earned ₹16.0 Cr.
Windlas Biotech Ltd earned ₹16.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹66.0 Cr. The 8-year compound rate is 25.1%. That is 6.7% of the quarter's revenue. The same quarter a year earlier earned ₹16.0 Cr.
Mar 26 profit was ₹16.0 Cr, +0.0% year on year. On the full year, FY26 printed ₹66.0 Cr (+8.2%), and the 8-year compound rate is 25.1%.
🚨 Why profit moved: revenue contributed +17.2% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +11.2% vs revenue +18.9%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
→ Profit rose — but did the cash follow? Next: 152% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 152% of Windlas Biotech Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹105 Cr of operating cash against ₹66.0 Cr of profit. After ₹76.0 Cr of capital spending, ₹29.0 Cr was left as free cash.
FY26: operating cash of ₹105 Cr against reported profit of ₹66.0 Cr, leaving free cash of ₹29.0 Cr after ₹76.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 152% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 152%: the cash cycle tightened 94 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 3.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹221 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Windlas Biotech Ltd's cash conversion cycle runs −24 days in FY26, down from 70 days in FY21. Capital spending ran ₹221 Cr over the last 3 years. At FY26 sales of ₹904 Cr each day of that cycle holds about ₹2.5 Cr, so roughly ₹−59.0 Cr sits inside the business at any moment.
FY26: debtors at 92 days, inventory at 40 days — roughly 1.3 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −24 days, tighter than FY21's 70.
The full loop: cash goes out to suppliers and production on day 0; stock waits 40 days to sell; customers pay about 92 days after that; and suppliers themselves are paid at 156 days — netting out to the −24-day cycle.
In money terms: at FY26 sales of ₹904 Cr, each day of the cycle holds about ₹2.5 Cr — so the −24-day loop keeps roughly ₹−59.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹221 Cr over the last 3 fiscal years against ₹72.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹60.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 16% and the ROIC − WACC spread is +5.6 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.⚠ unverified
Windlas Biotech Ltd earns a ROCE of 16% in FY26. That is up from a trough of 12% in FY20. Return on invested capital clears the cost of that capital by +5.6 percentage points, so growth here adds value rather than only size. The wiring behind it is 7.3% net margin on 1.00× asset turns.
FY26 ROCE is 16%, recovered from a FY20 trough of 12% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 7.3% net margin × 1.00× asset turns × 1.56× balance-sheet leverage ≈ 11.4% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 17.6% − 12.0% = a +5.6 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.06.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.⚠ unverified
Windlas Biotech Ltd carries total debt of ₹35.0 Cr against shareholder equity of ₹581 Cr as of Mar 26, a debt-to-equity of 0.06 — effectively unlevered. On the annual view that ratio went from 0.02 in FY22 to 0.06 in FY26. The returns elsewhere on this page are therefore earned rather than borrowed.
Mar 26: total debt of ₹35.0 Cr against shareholder equity of ₹581 Cr — a debt-to-equity of 0.06. On the annual view, debt-to-equity went from 0.02 (FY22) to 0.06 (FY26). The returns on this page are earned, not borrowed.
→ Who owns this, and are they adding or leaving? Next: the register is quiet.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
No holder of Windlas Biotech Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.3 points over the same window, to 9.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: +0.8 points over 8 quarters to 63.3%; Domestic institutions: +0.3 points over 8 quarters to 9.8%; Foreign institutions: +0.0 points over 8 quarters to 2.0%.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Windlas Biotech Ltd: the Z-score reads 5.62. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 5.62 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 5.62.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Windlas Biotech Ltd this page | 26.6× | ₹1,770 Cr | Mixed | |||
| Divis Laboratories Ltd | 73.4× | ₹1.9L Cr | Mixed | |||
| Laurus Labs Ltd | 79.1× | ₹86,505 Cr | Mixed | |||
| Anthem Biosciences Ltd | 73.1× | ₹43,360 Cr | No read | |||
| Gland Pharma Ltd | 37.6× | ₹39,257 Cr | Improving | |||
| Acutaas Chemicals Ltd | 75.2× | ₹26,785 Cr | Improving | |||
| Acutaas Chemicals Ltd | 69.1× | ₹26,686 Cr | Mixed | |||
| Sai Life Sciences Ltd | 73.8× | ₹26,174 Cr | No read | |||
| Piramal Pharma Ltd | — | ₹24,133 Cr | No read | |||
| Neuland Laboratories Ltd | 65.9× | ₹23,794 Cr | Turning around | |||
| Granules India Ltd | 31.8× | ₹20,655 Cr | Consistent | |||
| OneSource Specialty Pharma Ltd | — | ₹18,961 Cr | No read | |||
| Syngene International Ltd | 44.9× | ₹16,708 Cr | Turning around | |||
| Syngene International Ltd | 44.1× | ₹16,415 Cr | Turning around | |||
| Cohance Lifesciences Ltd | 80.9× | ₹15,957 Cr | Deteriorating | |||
| Jubilant Pharmova Ltd | 35.2× | ₹15,378 Cr | No read | |||
| Concord Biotech Ltd | 54.8× | ₹13,061 Cr | Deteriorating | |||
| Shilpa Medicare Ltd | 50.8× | ₹11,856 Cr | No read | |||
| Blue Jet Healthcare Ltd | 43.3× | ₹10,730 Cr | Deteriorating | |||
| Supriya Lifescience Ltd | 32.3× | ₹6,765 Cr | Consistent | |||
| IOL Chemicals & Pharmaceuticals Ltd | 30.0× | ₹4,380 Cr | Improving | |||
| SMS Pharmaceuticals Ltd | 35.0× | ₹3,569 Cr | Mixed | |||
| Morepen Laboratories Ltd | 39.6× | ₹2,948 Cr | Mixed | |||
| Dishman Carbogen Amcis Ltd | 29.0× | ₹2,878 Cr | No read | |||
| Hikal Ltd | 73.8× | ₹2,681 Cr | Deteriorating | |||
| Solara Active Pharma Sciences Ltd | 551.0× | ₹2,351 Cr | No read |
Frequently asked questions
What is Windlas Biotech Ltd's share price today?
Windlas Biotech Ltd trades at ₹844, −8.6% over the past year. The company is valued at ₹1,770 Cr. The stock sits at 37% of its 52-week range of ₹723–₹1,048, +1.2% versus its 200-day average. On the tape, the price is building a base, 7 weeks in. — as of 24 July 2026.
What were Windlas Biotech Ltd's latest quarterly results?
Windlas Biotech Ltd reported revenue of ₹238 Cr and net profit of ₹16.0 Cr for the Mar 26 quarter. Revenue rose 17.2% and profit rose 0.0% year on year. Earnings per share were ₹7.58. The operating margin was 11.0%, 2.0 pp lower than a year earlier. — as of 24 July 2026.
What is Windlas Biotech Ltd's revenue?
Windlas Biotech Ltd reported revenue of ₹238 Cr in the Mar 26 quarter, +17.2% year on year. For the full FY26 fiscal year, revenue was ₹904 Cr (+18.9%). Over the last 8 years revenue compounded at 12.5% a year. — as of 24 July 2026.
What is Windlas Biotech Ltd's profit?
Windlas Biotech Ltd earned ₹16.0 Cr of net profit in the Mar 26 quarter, +0.0% year on year. Full-year FY26 profit was ₹66.0 Cr. The operating margin ran 11.0% in the latest quarter. — as of 24 July 2026.
What is Windlas Biotech Ltd's market cap?
Windlas Biotech Ltd's market capitalisation is ₹1,770 Cr at a share price of ₹844. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Windlas Biotech Ltd's P/E ratio?
Windlas Biotech Ltd trades at a P/E of 26.6×, at the 71st percentile of its own 5-year range, against a long-run median of 21.2×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Windlas Biotech Ltd pay a dividend?
Yes — Windlas Biotech Ltd's dividend payout was 20% of profit in FY26, and it recorded a payout in 5 of its last 9 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Windlas Biotech Ltd overvalued?
On its own history, Windlas Biotech Ltd looks expensive against its own history: its P/E of 26.6× sits at the 71st percentile of its 5-year range (long-run median 21.2×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 24 July 2026.
Is Windlas Biotech Ltd growing?
The picture is mixed for Windlas Biotech Ltd: latest-quarter revenue +17.2% year on year, profit +0.0%, and the margin −2.0 pp at 11.0%. The 8-year compound rates are 12.5% (revenue) and 25.1% (profit). The earnings engine currently reads: mixed — as of 24 July 2026.
How is Windlas Biotech Ltd performing?
Windlas Biotech Ltd is building a base, 7 weeks in. Its latest quarter's revenue rose 17.2% and profit rose 0.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 4 weeks. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Windlas Biotech Ltd in?
Mixed — no clean majority across the growth curves, ROCE holding at 16.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +17.2% latest, profit growth +0.0% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Windlas Biotech Ltd in an uptrend?
No — the price is building a base (week 7 of stage 1), trading +1.2% versus its 200-day average and at 37% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Is Windlas Biotech Ltd beating the market?
On recent form, yes — Windlas Biotech Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 4 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4.9 years the stock moved +130% against the NIFTY 500's +66% — ahead of the index over the full window. — as of 24 July 2026.
Will Windlas Biotech Ltd's share price go up?
This page publishes no price forecast for Windlas Biotech Ltd. What it measures instead: the share price is ₹844, the price is building a base 7 weeks in. Its P/E of 26.6× sits at the 71st percentile of its own 5-year range. — as of 24 July 2026.
Who owns Windlas Biotech Ltd?
Promoters hold 63.3% of Windlas Biotech Ltd, foreign institutions 2.0%, domestic institutions 9.8% and the public 24.8% (latest quarter). No holder moved a full point over the last two years — the register is quiet. — as of 24 July 2026.
Does Windlas Biotech Ltd have too much debt?
No — Windlas Biotech Ltd's debt-to-equity is 0.06, and operating profit covers the interest bill 21×. FY26 borrowings were ₹35.0 Cr against equity of ₹581 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Windlas Biotech Ltd's capex?
Windlas Biotech Ltd spent ₹221 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹76.0 Cr, with ₹60.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Windlas Biotech Ltd's cash flow?
Windlas Biotech Ltd generated ₹105 Cr of operating cash flow in FY26 and ₹29.0 Cr of free cash flow after ₹76.0 Cr of capital spending. Reported profit that year was ₹66.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Windlas Biotech Ltd's profit real cash?
Yes — over the last 3 fiscal years, 152% of Windlas Biotech Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹105 Cr against reported profit of ₹66.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Windlas Biotech Ltd?
On the balance sheet, the Z-score reads 5.62 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Windlas Biotech Ltd in its business cycle?
Windlas Biotech Ltd's FY26 operating margin was 12.0%, against a 9-year band of 10.0%–13.0%: mid-band by its own history — neither the peak that precedes mean-reversion nor the trough that precedes recovery. The latest quarter ran 11.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Windlas Biotech Ltd story?
Biggest watch item: the P/E sits at the 71st percentile of its own range — the multiple has already done part of the work. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Windlas Biotech Ltd a stock worth studying right now?
This is not investment advice. The machine read: Windlas Biotech Ltd's three tracks disagree. Price, valuation and the earnings engine each tell a different story — the next quarter or two settles it. The sharpest open question: the next one or two quarters of delivery. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.